FindTrial
Sign In

Research of immunotherapy to prevent tumor recurrence of hepatic malignancies after liver transplantation

Research of immunotherapy to prevent tumor recurrence of hepatic malignancies after liver transplantation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-PNRC-12002354
Enrollment
Unknown
Registered
2012-07-13
Start date
2010-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

tumor recurrence of hepatic malignancies after liver transplantation

Interventions

Treatment group:Immunotherapy
Control:no

Sponsors

Tianjin First Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aging from 18 to 70 years old; 2. Liver transplantation forliver malignancies disease; 3. Volunteered to participate in this study, And signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Severe autoimmune diseases; 3. Uncontrollable infectious diseases; 4. Patients who are allergic to biological agents; 5. T-cell lymphoma.

Design outcomes

Primary

MeasureTime frame
T cell subsets;CD4 + T cells ATPase;cytokines (IL-1, IL-2, IL-6, IL-8);serum AFP;—

Countries

China

Contacts

Public ContactZhongyang Shen
sunxlx@yahoo.com.cn+86 13502038977

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026